Aimmune Therapeutics Inc. (AIMT)

24.21
0.63 2.67
NASDAQ : Health Technology
Prev Close 23.58
Open 23.75
Day Low/High 23.14 / 24.23
52 Wk Low/High 21.22 / 42.00
Volume 812.11K
Avg Volume 685.40K
Exchange NASDAQ
Shares Outstanding 58.73M
Market Cap 1.40B
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

There Are a Number of Justifications For Friday's Market Strength

There Are a Number of Justifications For Friday's Market Strength

Regardless of what is moving the markets, it is a good example of how you have to focus on price action above all else.

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

The stock's decline with the sector has occurred despite a steady supply of positive news.

The Market Is Transitioning Back to Stock Picking

The Market Is Transitioning Back to Stock Picking

There are obvious signs that people are trying to put cash to work.

Quiet Trading Allowing Some Biotech Names to Perk Up

Quiet Trading Allowing Some Biotech Names to Perk Up

After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.

No Market for Old Stock Pickers

No Market for Old Stock Pickers

As long as the indices remain under pressure there is no benefit to picking stocks.

What We Have This Morning Is Some Routine Flipping Into Strength

What We Have This Morning Is Some Routine Flipping Into Strength

My overall market view right now is to maintain a bullish bias but look for some pullbacks to support.

I'm Surprised by How Lifeless the Action Is

I'm Surprised by How Lifeless the Action Is

I find it difficult to believe that there won't be something positive out of the G-20 meeting.

Kohl's Stock Finds Itself Under Heavy Pressure

Kohl's Stock Finds Itself Under Heavy Pressure

The problem KSS faces is that reports from retailers are being automatically sold in this poor market right now.

My Options Strategy for These 2 Biotech Stocks

My Options Strategy for These 2 Biotech Stocks

It's weeks like this that I'm glad I have some 'dry powder' to deploy.

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Let's check out the charts and indicators.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

2 Biotech Stocks to Consider

2 Biotech Stocks to Consider

Many stocks are already at support levels and are offering opportunities to start some positions.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

There Is Still Plenty of Strong, Tradable Action

There Is Still Plenty of Strong, Tradable Action

This market may be extended by just about any measure, but that doesn't mean you should be fighting it.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

You Can't Reason With a Steamroller

You Can't Reason With a Steamroller

The momentum is crushing everything in its way.

Volume Slows Ahead of Christmas Holiday

Volume Slows Ahead of Christmas Holiday

Breadth is slightly negative as markets ease into 3-day weekend.

Blockchain Will Be a Top Investing Theme in 2018

Blockchain Will Be a Top Investing Theme in 2018

The applications for this distributed ledger technology are endless.

Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling

Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling

The republican loss in the Alabama special election for U.S. senate had only a brief imapct on stock futures.

As Dip Buyers Jump in, Stay Focused on Stock Picking

As Dip Buyers Jump in, Stay Focused on Stock Picking

Small-caps are lagging and breadth is negative, but the computer algorithms are very impressive.

Selling Subsides, but Market's Still a Mess

Selling Subsides, but Market's Still a Mess

Facebook, Alibaba sell off on very good reports.

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.